A 7-day oral treatment of patients with active rheumatoid arthritis using the prostacyclin analog iloprost: Cytokine modulation, safety, and clinical effects

Rheumatology International

Volumn 22, Issue 2, 2002, Pages 45-51

  Gao, Ino K ^a   Scholz, Peter ^b   Boehme, Michael W ^c   Norden, Cornelia ^b   Lemmel, Ernst Martin ^d  

^a Schering AG ^*  (Germany)

^b BAYER PHARMA AG   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

^d Max Grundig Clinic   (Germany)

Author keywords

Cytokine; Iloprost; Rheumatoid arthritis; TNF alpha inhibition

Indexed keywords

C REACTIVE PROTEIN; ILOPROST; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; PROSTACYCLIN DERIVATIVE; PROTEIN P55; PROTEIN P75; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; INTERLEUKIN DERIVATIVE; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ACTIVITY; DISEASE SEVERITY; DOSE CALCULATION; DOWN REGULATION; DRUG EFFECT; DRUG SAFETY; EDEMA; FEMALE; FOLLOW UP; HUMAN; MALE; MODULATION; PAIN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME; VISUAL ANALOG SCALE; BIOSYNTHESIS; BLOOD; CELL CULTURE; DOSE RESPONSE; HOSPITALIZATION; JOINT; LYMPHOCYTE ACTIVATION; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOLOGY; PATHOPHYSIOLOGY;

ADMINISTRATION, ORAL; ADULT; ARTHRITIS, RHEUMATOID; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMAN; ILOPROST; INTERLEUKINS; JOINTS; LIPOPOLYSACCHARIDES; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGE; RECEPTORS, TUMOR NECROSIS FACTOR; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR; HUMANS; MIDDLE AGED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0035985371     PISSN: 01728172     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00296-002-0187-x     Document Type: Article

References (24)

1. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α
2. Levels of circulating tumor necrosis factor α and interleukin-6 in patients with rheumatoid arthritis
3. TNF-α - A pivotal role in rheumatoid arthritis?
4. The tumor necrosis factor ligand and receptor families
5. Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor α antibody in rheumatoid arthritis
6. Randomised double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis
7. Repeated therapy with monoclonal antibody to tumor necrosis factor alpha (cA2) in patients with rheumatoid arthritis
8. Recombinant soluble tumor necrosis factor receptor (p80) fusion protein: Toxicity and dose finding trial in refractory rheumatoid arthritis
9. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc-fusion protein
10. Specific inhibition of tumour necrosis factor in endotoxin-stimulated mononuclear leukocytes by the prostacyclin analogue iloprost
11. Prostacyclin analogs are potent inhibitors of cytokine production by human monocytes
12. Prostacyclin analogs suppress the synthesis of tumor necrosis factor α in LPS-stimulated human peripheral blood mononuclear cells
13. Inhibition of the production and effect of TNF-alpha by iloprost: Possible impact for treatment of rheumatoid arthritis
14. Diminished inhibition of adhesion molecule expression in prostacyclin receptors desensitized human platelets
15. In-vitro/in-vivo correlation of drug liberation with an extended release per oral dosage form for iloprost in man
16. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis
17. Inhibition of tumor necrosis factor production in endotoxin-stimulated human mononuclear leukocytes by the prostacyclin analogue iloprost: Cellular mechanisms
18. Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti TNF-α therapy in rheumatoid arthritis
19. Two TNF receptors
20. Circadian relationships between interleukin (IL)-6 and hypothalamic-pituitary-adrenal axis hormones: Failure of IL-6 to cause sustained hypercortisolism in patients with early untreated rheumatoid arthritis
21. Prostacyclin analogues inhibit tissue factor expression in the human monocytic cell line THP-1 via a cyclic AMP-dependent mechanism
22. Intravenous iloprost infusion in patients with Raynaud's phenomenon secondary to systemic sclerosis
23. Oral iloprost as a treatment for Ray-naud's syndrome: A double blind multicentre placebo controlled study
24. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis